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Objective:To evaluate the impact of the presence ofCNSdisease
at diagnosis in the outcome of AML patients who underwent high-
dose chemotherapy and stem cell transplant. Methods: We per-
formed a retrospective study of all transplants performed for AML
in our institution between 1993 and 2007. Twenty-one patients
(11 males) with CNS disease were identified. Five had unclassified
AML, 2 M1, 2 M2, 9 M4 and 3 MDS. All but one patient had inter-
mediate or poor cytogenetics. Twelve patients were in remission (4
in CR1, 6 in CR2, 2 in greater CR) at the time of transplant. Four
patients had refractory relapse, 4 untreated relapse and one primary
induction failure. All patients were in CNS CR at the time of trans-
plant. Median age was 22.5 years (range 2–66). Three patients re-
ceived autologous graft. The conditioning regimen was
chemotherapy-based in 19 patients [Busulfan (Bu)-Fludarabine
(Flu): 6; Bu-Cyclophosphamide (Cy)-Thiotepa (TEP): 6; Flu-Mel-
phalan (Mel)-TEP: 2; Flu-Mel: 1; Flu-Mel-Mylotarg: 1; Bu-Cy: 1;
Decitabine-Bu-Cy:1; Cy-Etoposide:1]. Two patients received Flu-
Mel with TBI. GVHD prophylaxis was tacrolimus-based in 14/18
allogeneic transplants [with methotrexate (MTX) in 13 or steroids
in one], cyclosporine-based in 2 (one with MTX, one with steroids)
with 2 patients receiving T-cell depleted graft. The donor was
matched related in 9, matched unrelated in 4, mismatched related
in 4 and mismatched unrelated (cord) in 1. Eleven patients received
marrow, 9 PBSC and one cord blood transplant. Patients received
intrathecal chemotherapy monthly  6 months post-transplant as
CNS prophylaxis. Results: Twelve patients died (hemorrhage: 1,
sepsis: 2, acute GVHD: 2, MOF:1, chronic GVHD:1, relapse: 5).
With a median follow-up of 7.5 years, 9 patients are alive, 8 in
CCR, one inCR after CNS relapse and salvage chemotherapy.Con-
clusions:The presence of CNS disease at diagnosis should not pre-
clude the use of stem cell transplantation as treatment for AML.LYMPHOMA/MULTIPLE MYELOMA166
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The purpose of this study was to prospectively analyse minimal
residual disease (MRD) kinetics after reduced-intensity allogeneic
stem cell transplantation (allo-SCT) in high-risk chronic lympho-
cytic leukemia (CLL). Subjects were the first 30 consecutive pa-
tients from a prospective disease-specific multicenter clinical trial
by the German CLL Study Group (study patients), and 7 pilot pa-
tients treated identically. All patients had an unfavorable VHmuta-
tional status. Donor lymphocyte infusions (DLI) were administered
preemptively in case of incomplete chimerism and/or stable or in-
creasing MRD, provided that GVHD was absent after complete
withdrawal of immunosuppression.
Results: Using quantitative RQ-PCR and/or flow-based MRD
monitoring (sensitivity.510–4), four distinct patterns of MRD ki-
netics could be identified: (i) patients who achieved durable MRD
negativity without direct evidence of graft-versus-leukemia effects
(GVL; n 5 4); (ii) patients who showed a complete MRD response
to GVL (n5 18); (iii) patients who responded to GVL but failed to
reach complete MRD clearance (n 5 4); and (iv) patients in whom
a GVL effect with subsequent MRD suppression could not be in-
duced (n 5 2). Taking into account 2 non-relapse-related deaths,
study patients had a 54% probability of being alive and MRD-neg-
ative 12 months post transplant. MRD negativity occurring at this
time or later was durable in all cases except one. Three-year non-re-
lapse mortality, event-free, and overall survival of study patients was
11%, 58% and 71%, respectively.Conclusions: Effective GVL ac-tivity can be induced in most patients with high-risk CLL after allo-
SCT according to the design chosen here. GVL occurs essentially
in the context of chronic graft-versus-host disease induced by im-
munosuppression tapering or DLI. However, due to development
of secondaryGVL resistance, in a signficant proportion of cases sus-
tained MRD negativity is not achieved.167
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Background: Patients with CLL who are refractory to fludara-
bine have a median survival of 12 months. Reduced intensity condi-
tioning (RIC) for stem cell transplant may decrease transplant
related mortality (TRM) compared to full intensity conditioning
(FIC), but long term effectiveness is unclear. We compared out-
comes of 50 patients with advanced CLLwho underwent allogeneic
hematopoietic stem cell transplant (HSCT) at the University of
Michiganwith different intensity conditioning regimens.Methods:
Twenty one patients with CLL received RIC and 29 received FIC
prior to allogeneic HSCT between 1995 and 2005. RIC consisted
of Fludarabine (80–125 mg/m2) Busulfan (6.4 mg/kg IV or 8 mg/
kg oral) and Total lymphoid irradiation of 2–4 Gy. FIC consisted
of either CVB (cyclophosphamide 1800 mg/m2, etoposide 200
mg/m2 and BCNU 450 mg/m2) (n 5 20) or Bu/Cy (busulfan 3.2
mg/kg and cyclophosphamide 60 mg/kg for 2 days) (n 5 9). Graft
versus host disease prophylaxis consisted of tacrolimus and mycofe-
nolate mofetil in the RIC group and tacrolimus andmethotrexate in
the FIC group.Results:Themedian age was 56 years (range 41–61
years) in the RIC group and 50 years (range 26–61 years) in the FIC
group. There was no difference between groups regarding the num-
ber of prior therapies or stem cell source. High risk cytogenetics
were present in 50% (11/21) of the RIC group and 68% (20/29)
(del 17q13 or del 11q22 or complex cytogenetics) in the FIC group.
The donor source consisted of matched unrelated (MUD) 62% (13/
29) in the RIC and 45% (9/20) in the FIC group. RIC recipients
were significantly more likely to be alive at all times post HSCT
(5 y OS RIC 63% versus FIC 18%, p 5 0.006). High TRM was
the primary cause of inferior survival in the FIC recipients who ex-
perienced double the day 100TRM (FIC 27% versus RIC 14%, p5
0.005). The relapse rate was 14% regardless of conditioning regi-
men with the majority of relapses occurring after day 100. Likewise
the incidence of severe GVHD grade II-IV was similar in both
groups (FIC 27% versus RIC 28%). Conclusion: These data sug-
gest that RIC results in significant superior overall survival com-
pared to FIC in patients with CLL despite the higher proportion
of HLA-disparaty in the RIC group. The lower TRM in the RIC
group accounted for the major difference in overall survival.168
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Umbilical cord blood transplants (UCBT) from unrelated donors
is a feasible option for adults with high-risk acute leukemia. How-
ever, little is known about the outcome of UCBT in patients with
advanced lymphoid malignancies. We evaluated 104 adult patients
(median age, 41 years; range 16–65 years) who received a single
